Ferulic acid / ROS Cancer Research Results

FA, Ferulic acid: Click to Expand ⟱

Features:

Ferulic acid is an antioxidant found in some skin creams and serums.
Foods: popcorn, bamboo, whole-grain rye bread, whole-grain oat flakes, sweet corn (cooked)
Ferulic acid (FA) is a hydroxycinnamic acid abundant in plant cell walls (notably cereals/whole grains) with strong antioxidant and cytoprotective activity. Mechanistically, FA is frequently described as inducing Nrf2/HO-1 antioxidant programs and suppressing NF-κB-linked inflammation, with additional model-dependent anticancer effects (cell-cycle arrest, apoptosis, reduced invasion). Oral exposure is variable because FA is rapidly metabolized (often as conjugates) and bioaccessibility depends on the food matrix.

-Ferulic acid found in dietary strand fractions, especially its free form, has important functions for protecting the human health.
-AChE inhibitor (AD)
-Cooking results in an increase in free ferulic acid quantity and in a reduction in bound ferulic acid quantity.

Bamboo shoots       243.6 mg/100g
Sugar-beet pulp     800 mg/100g
Popcorn             313 mg/100g
Wheat bran	    500–1500mg/100g
Whole wheat flour   100–300mg/100g

Type of corn	p-coumaric acid	ferulic acid
	mg/kg, DW	mg/kg, DW
Yellow dent	18.9	265
American blue	N.D.	927
Mexican blue	1.3	202
white	6.6	2484

Pathway / Target	Modulation by FA / Direction
Aβ aggregation	         ↓ Inhibits fibril formation and destabilizes existing Aβ fibrils 
BACE‑1 & APP	         ↓ Reduces BACE-1 and APP expression; ↑ MMP‑2/‑9 expression promoting Aβ clearance
Tau hyperphosphorylation  Implicitly ↓ through modulation of Ca²⁺/CDK5/GSK3β pathways
Ca²⁺         	         ↓ FA lowers STEP levels via chelation of Ca²⁺, suppressing PP2B → restores synaptic plasticity
(AChE / BChE)	         ↓ Inhibition of AChE (FA IC₅₀~15 µM, derivatives IC₅₀ down to 0.006 µM); also BChE
(MAO‑A/B)	         ↓ Inhibits MAO‑B (derivatives IC₅₀ ~0.3–0.7 µM), reducing ROS
ROS                      ↓ Scavenges ROS, enhances antioxidant enzymes (e.g., catalase), ↓ MDA
(COX‑2, 5‑LOX, NLRP3)	 ↓ Derivatives inhibit COX‑2/5‑LOX; derivative 13a ↓ NLRP3 inflammasome
Iron/Cu²⁺ chelation	 ↓ Metal-induced Aβ aggregation via chelation by FA and derivatives
Autophagy & Aβ clearance  ↗ Suggested promotion of autophagy mechanisms targeting Aβ

Ferulic acid — Ferulic acid is a naturally occurring hydroxycinnamic phenolic acid concentrated in plant cell walls, particularly in cereal bran, whole grains, rice bran, corn, oats, wheat, bamboo shoots, and some fruits and vegetables. It is formally classified as a dietary polyphenol and phenolic antioxidant; the standard abbreviation is FA. Most food-derived FA is ester-linked to arabinoxylans, lignin, and other structural polysaccharides, whereas free FA is more readily absorbed. FA has predominantly antioxidant and cytoprotective activity in normal tissues, but can produce antiproliferative, pro-oxidant, mitochondrial, apoptotic, pyroptotic, and anti-invasive effects in susceptible cancer models. It is not an approved anticancer drug.

Primary mechanisms (ranked):

Induction of cancer-cell growth arrest and mitochondrial cell death through suppression of PI3K/AKT/mTOR, STAT3, cyclins, and CDKs, with activation of p53, p21, BAX, caspases, and related stress pathways.
Context-dependent redox disruption in cancer cells, including ROS accumulation, glutathione and antioxidant-enzyme depletion, mitochondrial dysfunction, lipid peroxidation, and ROS/JNK/BAX-dependent apoptosis or pyroptosis.
Suppression of EMT, migration, invasion, angiogenesis, and metastasis through modulation of MMP2, MMP9, VEGF, β-catenin/ZEB1, vimentin, E-cadherin, NF-κB, and related pathways.
Inhibition of glycolytic and anabolic signalling, including reductions in c-MYC, PKM2, LDH, CAIX, PI3K/AKT/mTOR, and tumor-associated glycolysis in selected models.
Modulation of DNA-damage responses and cell-cycle checkpoints, including ATM, ATR, CHK1/2, γH2AX, p53, p21, CDC25, CDK2, CDK4/6, and cyclin D1.
Suppression of tumor-promoting inflammatory signalling, particularly NF-κB, COX-2, JAK2/STAT3, inflammatory cytokines, and related mediators.
NRF2/HO-1 and direct radical-scavenging activity are central to normal-cell protection but are secondary and context-dependent in cancer, where antioxidant signalling could theoretically protect some tumors from oxidative therapies.

Bioavailability / PK relevance: Orally administered FA is absorbed from the stomach and small intestine, with additional release and microbial conversion of cereal-bound FA in the colon. It undergoes rapid first-pass glucuronidation, sulfation, methylation, and glycine conjugation; circulating material is predominantly conjugated rather than free FA. Food-matrix binding is a major constraint: free FA and processed or enzymatically released FA are more bioavailable than intact bran-bound FA. Human cereal studies have reported free or equivalent plasma concentrations in the low-nanomolar range, while pharmacokinetic results from herbal mixtures cannot be directly extrapolated to purified FA. Nanoencapsulation, phospholipid carriers, ester derivatives, and enzymatic liberation from bran can increase exposure experimentally, but none is established for oncology.

In-vitro vs systemic exposure relevance: Most anticancer experiments use approximately 25–500 µM FA, with many cytotoxic effects occurring at 100 µM or higher. These concentrations substantially exceed the low-nanomolar free FA levels typically observed after ordinary dietary intake and likely exceed sustained free systemic exposure achievable with conventional oral preparations. Therefore, direct systemic tumor cytotoxicity from dietary FA is pharmacokinetically implausible. Local gastrointestinal exposure, metabolites, repeated dosing, formulated delivery, or pharmacological derivatives may be more relevant than plasma free-FA concentrations.

Clinical evidence status: Cancer evidence is preclinical, consisting mainly of cultured cancer cells and rodent xenograft or carcinogenesis models. There are no established oncology RCTs showing tumor response, progression-free survival, or overall-survival benefit from purified FA. Radiosensitization and chemosensitization have been reported experimentally, but FA also protects normal tissues from radiation and chemotherapy injury; the net interaction is treatment-, timing-, dose-, and tissue-dependent. Human evidence is limited mainly to dietary bioavailability, topical dermatology, cardiovascular or metabolic observations, and combination supplements studied in cognitive impairment. FA should not be classified as a clinically validated anticancer therapy.

Ferulic Acid Mechanistic Profile

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	PI3K AKT mTOR survival signalling	PI3K ↓; AKT ↓; mTOR ↓; PTEN ↑ (model-dependent)	AKT ↔ or ↑ during injury protection	R, G	Growth inhibition and apoptosis sensitization	A recurrent anticancer axis, although direction in normal stressed tissue may differ from that in malignant cells.
2	Mitochondrial apoptosis	Mitochondrial membrane potential ↓; BAX ↑; BCL-2 ↓; cytochrome c release ↑; caspase-9 ↑; caspase-3 ↑; apoptosis ↑	Mitochondrial injury ↓; apoptosis ↓ under toxic or inflammatory stress	R, G	Intrinsic cell-death execution	Common downstream phenotype in susceptible cancer models; frequently concentration- and cell-line-dependent.
3	Cancer-cell ROS and pyroptotic stress	ROS ↑; JNK ↑; BAX ↑; GSDMD processing ↑; apoptosis or pyroptosis ↑ (model-dependent)	ROS ↓; lipid peroxidation ↓; oxidative injury ↓	P, R, G	Selective redox overload	FA is not uniformly antioxidant in cancer. A ROS/JNK/BAX/GSDMD mechanism has been reported in lung-cancer models, but is not established across tumor types.
4	Cell-cycle checkpoint control	p53 ↑; p21 ↑; CHK1/2 ↑; CDC25 ↓; CDK2 ↓; CDK4/6 ↓; cyclin D1 ↓; arrest ↑	↔	G	Cytostasis	The specific arrest phase varies among models and may include G0/G1, S-phase, or G2/M accumulation.
5	EMT invasion and metastasis	EMT ↓; MMP2 ↓; MMP9 ↓; vimentin ↓; β-catenin/ZEB1 ↓; migration ↓; invasion ↓	↔	G	Anti-invasive and antimetastatic phenotype	Supported principally by cell migration assays and animal tumor models rather than clinical evidence.
6	NF-κB inflammatory signalling	NF-κB ↓; COX-2 ↓; inflammatory cytokines ↓; survival signalling ↓	NF-κB ↓; COX-2 ↓; iNOS ↓; TNF-α ↓; IL-1β ↓; IL-6 ↓	R, G	Reduced inflammation and tumor-promoting signalling	This mechanism is more consistently protective and anti-inflammatory than directly cytotoxic.
7	Glycolysis and anabolic metabolism	c-MYC ↓; PKM2 ↓; LDH ↓; CAIX ↓; glycolysis ↓ (model-dependent)	↔	G	Metabolic growth restriction	Potentially important in highly glycolytic tumors but supported by fewer models than apoptosis and cell-cycle regulation.
8	STAT and growth-factor signalling	JAK2 ↓; phosphorylated STAT3 ↓; STAT6 ↓; FGFR1 ↓; FGFR2 ↓; proliferation ↓	↔	R, G	Suppression of proliferative transcription	Individual targets are tumor-model-specific and should not be treated as universal direct molecular targets of FA.
9	Angiogenesis	VEGF ↓; angiogenesis ↓	VEGF ↔ or ↑ during tissue repair (context-dependent)	G	Reduced tumor vascular support	Potentially opposite modulation in ischemic or reparative normal tissue illustrates the context dependence of FA.
10	DNA damage response	ATM ↑; ATR ↑; CHK1/2 ↑; γH2AX ↑; DNA damage ↑ (high concentration only)	DNA oxidative damage ↓	R, G	Checkpoint activation and tumor-cell death	At pharmacological concentrations, FA may promote cancer-cell stress while protecting normal DNA through antioxidant activity.
11	NRF2 HO-1 antioxidant response	NRF2 ↔ or ↑ (context-dependent); possible tumor stress adaptation	NRF2 ↑; ARE ↑; HO-1 ↑; NQO1 ↑; GCLC ↑; GCLM ↑; GSH ↑	R, G	Endogenous antioxidant defence	A core cytoprotective mechanism in normal tissues but not necessarily therapeutically favourable in NRF2-dependent tumors.
12	Mitochondrial dynamics and tissue protection	Not consistently defined	DRP1 ↓; FIS1 ↓; MFN1 ↑; MFN2 ↑; OPA1 ↑; mitochondrial damage ↓	R, G	Preservation of mitochondrial integrity	Reported mainly in toxic, metabolic, cardiovascular, or neurological injury models.
13	Radiosensitization and radioprotection	Radiosensitization ↑ in selected models; DNA damage and apoptosis ↑ (model-dependent)	Radiation-induced ROS ↓; inflammation ↓; tissue injury ↓; radioprotection ↑	R, G	Bidirectional radiation interaction	Timing and tissue selectivity are critical. Normal-tissue radioprotection does not establish improved tumor control and could theoretically reduce efficacy under some conditions.
14	Chemosensitization and treatment toxicity	Chemosensitivity ↑ in selected drug and cell-line combinations	Chemotherapy-associated oxidative or inflammatory injury ↓	R, G	Adjunct modulation	No standardized human oncology dosing or validated treatment combination has been established.
15	Clinical Translation Constraint	Free systemic FA exposure is far below many cytotoxic in-vitro concentrations	Rapid conjugation; matrix-dependent absorption; generally dietary exposure	—	Limited systemic anticancer translation	Most experiments use tens to hundreds of micromolar FA, whereas human dietary exposure produces predominantly conjugated metabolites and low free plasma concentrations.

P: 0–30 min R: 30 min–3 hr G: >3 hr

Alzheimer’s disease relevance: Ferulic acid has substantial preclinical relevance to Alzheimer’s disease through direct inhibition of amyloid-β aggregation, attenuation of APP and BACE1 processing, reduction of tau phosphorylation, suppression of neuroinflammation and oxidative injury, metal chelation, preservation of mitochondrial function, and modulation of cholinergic signalling. FA and several FA-derived multifunctional compounds inhibit AChE or BChE in vitro, but the potency of derivatives should not be attributed to unmodified FA. Small human studies have evaluated combination products containing FA and Angelica archangelica extract in mild cognitive impairment or dementia-related symptoms; these do not establish efficacy of isolated FA or demonstrate disease modification. The clinical evidence remains preliminary and formulation-specific.

AD clinical evidence status: Strong preclinical evidence; limited small human combination-product studies; no confirmatory phase III trial; no regulatory approval for prevention or treatment of Alzheimer’s disease. Reported cognitive findings require replication using isolated FA, adequate sample sizes, biomarker-defined populations, validated dosing, and longer follow-up.

Ferulic Acid in Alzheimer’s Disease

Rank	Pathway / Axis	Modulation	TSF	Primary Effect	Notes / Interpretation
1	Amyloid beta aggregation	Aβ oligomerization ↓; fibril formation ↓; existing fibril stability ↓	P, R	Reduced amyloid aggregation	Direct anti-aggregation effects are demonstrated mainly in biochemical and cellular systems at concentrations not clearly achieved in human brain tissue.
2	APP BACE1 amyloid production	APP ↓; BACE1 ↓; amyloidogenic processing ↓	G	Reduced Aβ generation	Supported mainly by cellular and animal models.
3	Oxidative stress and NRF2 HO-1	ROS ↓; lipid peroxidation ↓; NRF2 ↑; HO-1 ↑; NQO1 ↑; GSH ↑; antioxidant enzymes ↑	P, R, G	Neuronal redox protection	One of the most consistent neuroprotective mechanisms across toxicant and neurodegeneration models.
4	Neuroinflammation	NF-κB ↓; NLRP3 ↓; COX-2 ↓; iNOS ↓; TNF-α ↓; IL-1β ↓; IL-6 ↓	R, G	Reduced inflammatory neuronal injury	Predominantly demonstrated in animal and glial-cell models.
5	Tau kinase and phosphatase balance	GSK3β activity ↓; CDK5 dysregulation ↓; tau hyperphosphorylation ↓ (model-dependent)	R, G	Reduced tau pathology	The exact upstream mechanism varies and may involve calcium signalling, AKT, ERK, and oxidative-stress regulation.
6	Cholinergic signalling	AChE ↓; BChE ↓; acetylcholine availability ↑; ChAT ↑ (model-dependent)	P, R, G	Improved cholinergic transmission	Unmodified FA is generally less potent than optimized FA derivatives; derivative potency must be recorded separately.
7	Mitochondrial function	Mitochondrial ROS ↓; membrane-potential loss ↓; ATP preservation ↑; DRP1 ↓; FIS1 ↓; MFN1 and MFN2 ↑	R, G	Preserved neuronal bioenergetics	Evidence derives mainly from oxidative, toxicant, and ischemic injury models.
8	Calcium dependent synaptic dysfunction	Pathological Ca²⁺ signalling ↓; calcineurin PP2B signalling ↓; STEP ↓ (model-dependent)	P, R	Preserved synaptic plasticity	The description of FA as directly chelating neuronal calcium should be used cautiously; pathway modulation is better supported than clinically meaningful systemic calcium chelation.
9	Metal associated amyloid toxicity	Iron and Cu²⁺ coordination ↑; metal-driven ROS and Aβ aggregation ↓	P, R	Reduced metal-mediated oxidative aggregation	Most evidence is biochemical. Brain exposure sufficient for clinically meaningful chelation has not been established.
10	Autophagy and proteostasis	Autophagic clearance ↔ or ↑ (model-dependent); Aβ clearance ↑	G	Improved aggregate disposal	Autophagy findings are inconsistent and should not be represented as a universal FA mechanism.
11	Clinical Translation Constraint	Brain exposure uncertain; extensive conjugation; human evidence derived largely from combination products	—	Unproven disease modification	No validated isolated-FA dose, target-engagement biomarker, or confirmatory Alzheimer’s disease trial is available.

P: 0–30 min R: 30 min–3 hr G: >3 hr

ROS, Reactive Oxygen Species: Click to Expand ⟱

Source: HalifaxProj (inhibit)

Type:

Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)
ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
• Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
• HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
• SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
• AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
• mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
• HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
• Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy

ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination


Item  ROS↑  NRF2  Condition  Mechanism Class  Remarks  

ROS">Piperlongumine
+++  ↓  [D][T]  ROS-dominant
Selective <span class="wphighlight">ROS</span> stressor, Prevents compensatory upregulation of NRF2, ie GSH↓



ROS">Shikonin
+++ ↓/± [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + glycolysis + GPX4 inhibition



ROS">Vitamin K3 (menadione)
+++ ↓ [D] ROS-dominant
Quinone redox cycler; toxicity limits use



ROS">Copper (ionic / nano)
+++ ↓ [Fe][F] ROS-dominant
Fenton-type redox chemistry



ROS">Sodium Selenite
+++ ↓ [D] ROS-dominant
Pro-oxidant, depletes GSH



ROS">Juglone
+++ ↓ [D] ROS-dominant
Strong quinone <span class="wphighlight">ROS</span> chemistry



ROS">Auranofin
+++ ↓ [D] ROS-dominant
TrxR inhibition → redox collapse



ROS">Photodynamic Therapy (PDT)
+++ 0 [L][O₂] ROS-dominant
Singlet oxygen is core cytotoxic mechanism



ROS">Radiotherapy / Radiation
+++ 0 [O₂] ROS-dominant
DNA damage largely via <span class="wphighlight">ROS</span>



ROS">Doxorubicin
+++ ↓ [D] ROS-dominant
Chemo; redox cycling + mitochondrial <span class="wphighlight">ROS</span>



ROS">Cisplatin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> contributes to DNA/protein damage



ROS">Salinomycin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated CSC toxicity



ROS">Artemisinin / DHA
++ ↓ [Fe][T] ROS-dominant
Iron-activated radical generation



ROS">Sulfasalazine
++ ↓ [C][T] ROS-dominant
Ferroptosis; xCT inhibition → lipid <span class="wphighlight">ROS</span>



ROS">FMD / fasting
++ ↓ [M][C][O₂] ROS-dominant
Metabolic stress → mitochondrial <span class="wphighlight">ROS</span>



ROS">Vitamin C (pharmacologic)
++ ↓ [Fe][D] ROS-dominant
Extracellular H₂O₂ at high dose



ROS">Silver nanoparticles
++ ± [F][D] ROS-dominant
<span class="wphighlight">ROS</span> common; selectivity unreliable



ROS">Gambogic acid
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Parthenolide
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + NF-κB suppression



ROS">Plumbagin
++ ↓ [D] ROS-dominant
Quinone <span class="wphighlight">ROS</span> driver



ROS">Allicin
++ ↓ [D] ROS-dominant
Thiol-reactive oxidative stress



ROS">Ashwagandha (Withaferin A)
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Berberine
++ ↓ [D][M] ROS-dominant
Mitochondrial <span class="wphighlight">ROS</span> induction



ROS">PEITC
++ ↓ [D][C] ROS-dominant
GSH depletion + <span class="wphighlight">ROS</span>



ROS">Methionine restriction
+ ↓ [M][C][T] ROS-secondary
Redox vulnerability increased; <span class="wphighlight">ROS</span> indirect



ROS">DCA
+ ± [M][T] ROS-secondary
<span class="wphighlight">ROS</span> via forced OXPHOS



ROS">Capsaicin
+ ± [D][T] ROS-secondary
Ca²⁺ stress → <span class="wphighlight">ROS</span>



ROS">Galloflavin
+ 0 [D] ROS-secondary
<span class="wphighlight">ROS</span> not primary driver



ROS">Piperine
+ ± [D][F] ROS-secondary
Weak <span class="wphighlight">ROS</span> induction



ROS">Propyl gallate
+ ↓ [D] ROS-secondary
Pro-oxidant at high dose



ROS">Scoulerine
+ ? [D][T] ROS-secondary
Sparse <span class="wphighlight">ROS</span> data



ROS">Thymoquinone
± ± [D][T] Dual redox
Antioxidant ↔ pro-oxidant switch



ROS">Emodin
± ± [D][T] Dual redox
Not cancer-exclusive



ROS">Alpha-lipoic acid (ALA)
± ↑ [D][M] NRF2-dominant
Antioxidant at low dose



ROS">Curcumin
± ↑/↓ [D][F] NRF2-dominant
Hormetic redox behavior



ROS">EGCG
± ↑/↓ [D][O₂] NRF2-dominant
Auto-oxidation artifacts common



ROS">Quercetin
± ↑/↓ [D][Fe] NRF2-dominant
GSH-dependent cycling



ROS">Resveratrol
± ↑ [D][M] NRF2-dominant
<span class="wphighlight">ROS</span> only at high dose



ROS">Sulforaphane
± ↑↑ [D] NRF2-dominant
Strong NRF2 activator



ROS">Lycopene
0 ↑ — Antioxidant
Consistently antioxidant



ROS">Rosmarinic acid
0 ↑ — Antioxidant
Primarily antioxidant



ROS">Citrate
0 0 — Neutral
Metabolic; not a <span class="wphighlight">ROS</span> agent

Scientific Papers found: Click to Expand⟱

6873-

FA,

Ferulic acid: extraction, estimation, bioactivity and applications for human health and food

Review,

Nor,

*Inflam↓, *AntiBio↑, AntiCan↑, *AntiDiabetic↑, *cardioP↑, *neuroP↑, *ROS↓, *antiOx↑, *AGEs↓, *Catalase↑, *SOD↑,

6865-

FA,

Ferulic Acid Regulates GSDMD through the ROS/JNK/Bax Mitochondrial Apoptosis Pathway to Induce Pyroptosis in Lung Cancer

in-vitro,

Lung,

TumCP↓, MMP↓, LDH↑, Pyro↑, GSDMD↑, ROS↑, JNK↑, BAX↑,

3783-

FA,

Design, Synthesis, and Biological Evaluation of Ferulic Acid-Piperazine Derivatives Targeting Pathological Hallmarks of Alzheimer’s Disease

NA,

AD,

*ROS↓, *IronCh↑, *NLRP3↓, *Aβ↓, *AChE↓, *BChE↓, *antiOx↑, *BBB↑, *MMP↑, *memory↑, *SOD↑, *Catalase↑,

6877-

FA,

The protective role of ferulic acid on sepsis-induced oxidative damage in Wistar albino rats

in-vivo,

Nor,

Wistar albino rats

*antiOx↑, *Inflam↓, *AntiCan↑, *hepatoP↑, *DNAdam↓, *Sepsis↓, *MDA↓, *GSH↑, *GPx↑, *ROS↓,

6881-

FA,

Potential Therapeutic Efficacy of Ferulic Acid and Its Derivatives in the Management of Cancers: A Comprehensive Analysis With Mechanistic Insight

Review,

Var,

ROS↑, TumCCA↑, TumCI↓, TumCMig↓, TumCP↓, BioAv↑, BioAv↑, TP53↑, CDK2↓, CDK4↓, CDK6↓, JAK2↓, STAT6↓, tyrosinase↓, p‑Akt↓, p‑PI3K↓, mTOR↓, Ki-67↓, Casp3↑, proCasp8↑, cl‑PARP↑, BAX↑, Bcl-2↓, Mcl-1↓, MMP9↓, cycD1/CCND1↓, cycE/CCNE↓, PINK1↑, PARK2↑, MMP↓, CycD3↓, TumAuto⇅, eff↑, eff↑, ALAT↓, AST↓, ALP↓, VEGF↓, MMPs↓, angioG↓,

6885-

FA,

Mitigation of renal toxicity induced by paraquat using ferulic acid: Role of inflammatory pathways

in-vivo,

Nor,

Thirty-two male Wistar rats

*Dose↝, *TAC↑, *MDA↓, *RenoP↑, *PI3K↓, *Akt↓, *ROS↓, *Inflam↓, PPARγ↝, *NF-kB↓, *IL6↓, *TNF-α↓, *iNOS↓, *ALAT↓, *AST↓, *Urea↓, *Catalase↑, *SOD↑, *GPx↑, *GSH↑,

6886-

FA,

MTX,

Ferulic acid prevents oxidative stress, inflammation, and liver injury via upregulation of Nrf2/HO-1 signaling in methotrexate-induced rats

in-vivo,

Nor,

methotrexate-induced rats

*hepatoP↑, *ROS↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *p65↓, *BAX↓, *Casp3↓, *NRF2↑, *HO-1↑, *PPARγ↑, *Inflam↓,

1654-

FA,

Molecular mechanism of ferulic acid and its derivatives in tumor progression

Review,

Var,

AntiCan↑, Inflam↓, RadioS↑, ROS↑, Apoptosis↑, TumCCA↑, TumCMig↑, TumCI↓, angioG↓, ChemoSen↑, ChemoSideEff↓, P53↑, cycD1/CCND1↓, CDK4↓, CDK6↓, TumW↓, miR-34a↑, Bcl-2↓, Casp3↑, BAX↑, β-catenin/ZEB1↓, cMyc↓, Bax:Bcl2↑, SOD↓, GSH↓, LDH↓, ERK↑, eff↑, JAK2↓, STAT6↓, NF-kB↓, PYCR1↓, PI3K↓, Akt↓, mTOR↓, Ki-67↓, VEGF↓, FGFR1↓, EMT↓, CAIX↓, LC3II↑, p62↑, PKM2↓, Glycolysis↓, *BioAv↓,

1656-

FA,

Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling

Review,

Var,

tyrosinase↓, CK2↓, TumCP↓, TumCMig↓, FGF↓, FGFR1↓, PI3K↓, Akt↓, VEGF↓, FGFR1↓, FGFR2↓, PDGF↓, ALAT↓, AST↓, TumCCA↑, CDK2↓, CDK4↓, CDK6↓, BAX↓, Bcl-2↓, MMP2↓, MMP9↓, P53↑, PARP↑, PUMA↑, NOXA↑, Casp3↑, Casp9↑, TIMP1↑, lipid-P↑, mtDam↑, EMT↓, Vim↓, E-cadherin↓, p‑STAT3↓, COX2↓, CDC25↓, RadioS↑, ROS↑, DNAdam↑, γH2AX↑, PTEN↑, LC3II↓, Beclin-1↓, SOD↓, Catalase↓, GPx↓, Fas↑, *BioAv↓, cMyc↓, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↓,

3710-

FA,

Therapeutic Potential of Ferulic Acid in Alzheimer's Disease

Review,

AD,

*antiOx↑, *AntiCan↑, *Inflam↓, *hepatoP↑, *cardioP↑, *neuroP↑, *Aβ↓, *ROS↓, *AChE↓,

3712-

FA,

Ferulic Acid: A Hope for Alzheimer’s Disease Therapy from Plants

Review,

AD,

*antiOx↑, *Inflam↓, *ROS↓, *Aβ↓, *HO-1↑, *HSP70/HSPA5↑, *ERK↑, *Akt↑, *iNOS↓, *COX2↓, *cardioP↑, *memory↑, *IL2↓, *cognitive↑, *APP↓, *SOD↑, *Catalase↑, *Akt↑, *BioAv↑,

3713-

FA,

Protective Effect of Ferulic Acid on Acetylcholinesterase and Amyloid Beta Peptide Plaque Formation in Alzheimer’s Disease: An In Vitro Study

Review,

AD,

*AChE↓, *antiOx↑, *neuroP↑, *Aβ↓, *MMP↓, *XO↓, *SOD↑, *lipid-P↑, *ROS↓,

3714-

FA,

Recent Advances in the Neuroprotective Properties of Ferulic Acid in Alzheimer's Disease: A Narrative Review

Review,

AD,

*antiOx↑, *Inflam↓, *neuroP↑, *NF-kB↓, *NLRP3↓, *iNOS↓, *COX2↓, *TNF-α↓, *IL1β↓, *VCAM-1↓, *ICAM-1↓, *p‑MAPK↓, *p38↓, *JNK↓, *IL6↓, *IL8↓, *hepatoP↑, *RenoP↑, *Catalase↑, *PPARγ↑, *ROS↓, *Fenton↓, *IronCh↑, *SOD↑, *MDA↓, *lipid-P↓, *NRF2↑, *HO-1↑, *ARE↑, *Bil↑, *radioP↑, *GCLC↑, *GCLM↑, *NQO1↑, *Half-Life↝, *GutMicro↑, *Aβ↓, *BDNF↑, *Ca+2↓, *lipid-P↓, *PGE2↓, *cognitive↑, *ChAT↑, *memory↑, *Dose↝, *toxicity↓,

3718-

FA,

Therapeutic potential of ferulic acid and its derivatives in Alzheimer's disease-A systematic review

Review,

AD,

*antiOx↑, *ROS↓, *Inflam↓,

3778-

FA,

Recent Advances in the Neuroprotective Properties of Ferulic Acid in Alzheimer’s Disease: A Narrative Review

Review,

AD,

*neuroP↑, *Aβ↓, *antiOx↑, *Inflam↓, *ROS↓, *NF-kB↓, *NLRP3↓, *iNOS↓, *COX2↓, *TNF-α↓, *IL1β↓, *VCAM-1↓, *ICAM-1↓, *p‑MAPK?, *hepatoP↑, *TLR4↓, *PPARγ↑, *NRF2↑, *Fenton↓, *IronCh↑, *MDA↓, *HO-1↑, *Bil↑, *GCLC↑, *GCLM↑, *NQO1↑, *GutMicro↑, *SOD↑, *Ca+2↓, *lipid-P↓, *PGE2↓,

3782-

FA,

Ferulic acid ameliorates bisphenol A (BPA)-induced Alzheimer’s disease-like pathology through Akt-ERK crosstalk pathway in male rats

in-vivo,

AD,

Rats

*cognitive↑, *ERK↓, *p‑Akt↓, *AChE↓, *BACE↓, *neuroP↑, *ROS↓, *MDA↓, *GSH↑, *GSSG↓, *p‑tau↓, *lipid-P↓, *Aβ↓,

Showing Research Papers: 1 to 16 of 16

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 16

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 9, ARE↑, 1, Bil↑, 2, Catalase↑, 5, Fenton↓, 2, GCLC↑, 2, GCLM↑, 2, GPx↑, 2, GSH↑, 3, GSSG↓, 1, HO-1↑, 4, lipid-P↓, 4, lipid-P↑, 1, MDA↓, 5, NQO1↑, 2, NRF2↑, 3, ROS↓, 12, SOD↑, 7, TAC↑, 1,

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 3,

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1, MMP↑, 1,

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1, PPARγ↑, 3,

Cell Death(tgid=5) ⓘ

Akt↓, 1, Akt↑, 2, p‑Akt↓, 1, BAX↓, 1, Casp3↓, 1, iNOS↓, 4, JNK↓, 1, p‑MAPK?, 1, p‑MAPK↓, 1, p38↓, 1,

Protein Folding & ER Stress(tgid=8) ⓘ

HSP70/HSPA5↑, 1,

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1, ERK↑, 1, PI3K↓, 1,

Migration(tgid=13) ⓘ

APP↓, 1, Ca+2↓, 2, VCAM-1↓, 2,

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 3, ICAM-1↓, 2, IL1β↓, 3, IL2↓, 1, IL6↓, 2, IL8↓, 1, Inflam↓, 9, NF-kB↓, 4, p65↓, 1, PGE2↓, 2, TLR4↓, 1, TNF-α↓, 4,

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 4, BChE↓, 1, BDNF↑, 1, ChAT↑, 1, p‑tau↓, 1,

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1, Aβ↓, 7, BACE↓, 1, NLRP3↓, 3, XO↓, 1,

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2, BioAv↑, 1, Dose↝, 2, Half-Life↝, 1,

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1, AST↓, 1, Bil↑, 2, GutMicro↑, 2, IL6↓, 2, Urea↓, 1,

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2, AntiDiabetic↑, 1, cardioP↑, 3, cognitive↑, 3, hepatoP↑, 5, memory↑, 3, neuroP↑, 6, radioP↑, 1, RenoP↑, 2, toxicity↓, 1,

Infection & Microbiome(tgid=24) ⓘ

Sepsis↓, 1,
Total Targets: 87

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species

16 Ferulic acid
1 methotrexate

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:77  Target#:275  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Ferulic acid / ROS Cancer Research Results

Ferulic Acid Mechanistic Profile

Ferulic Acid in Alzheimer’s Disease

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress(tgid=1) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Core Metabolism/Glycolysis(tgid=4) ⓘ

Cell Death(tgid=5) ⓘ

Autophagy & Lysosomes(tgid=9) ⓘ

DNA Damage & Repair(tgid=10) ⓘ

Cell Cycle & Senescence(tgid=11) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Migration(tgid=13) ⓘ

Angiogenesis & Vasculature(tgid=14) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Hormonal & Nuclear Receptors(tgid=20) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Clinical Biomarkers(tgid=22) ⓘ

Functional Outcomes(tgid=23) ⓘ

Pathway results for Effect on Normal Cells:

NA, unassigned(tgid=0) ⓘ

Redox & Oxidative Stress(tgid=1) ⓘ

Metal & Cofactor Biology(tgid=2) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Core Metabolism/Glycolysis(tgid=4) ⓘ

Cell Death(tgid=5) ⓘ

Protein Folding & ER Stress(tgid=8) ⓘ

DNA Damage & Repair(tgid=10) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Migration(tgid=13) ⓘ

Barriers & Transport(tgid=15) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Synaptic & Neurotransmission(tgid=18) ⓘ

Protein Aggregation(tgid=19) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Clinical Biomarkers(tgid=22) ⓘ

Functional Outcomes(tgid=23) ⓘ

Infection & Microbiome(tgid=24) ⓘ

Home Page